Decitabine + Valproic Acid

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndrome

Conditions

Myelodysplastic Syndrome, Acute Myelogenous Leukemia

Trial Timeline

Dec 1, 2006 → May 1, 2015

NCT ID

NCT00414310

About Decitabine + Valproic Acid

Decitabine + Valproic Acid is a phase 2 stage product being developed by Eisai for Myelodysplastic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00414310. Target conditions include Myelodysplastic Syndrome, Acute Myelogenous Leukemia.

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndrome were approved

Approved (7) Terminated (7) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00414310	Phase 2	Completed	Dec 1, 2006	May 1, 2015	Myelodysplastic Syndrome
NCT00075010	Phase 1/2	Completed	Jan 23, 2004	Nov 8, 2006	Leukemia

Competing Products

20 competing products in Myelodysplastic Syndrome

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35
Decitabine	Johnson & Johnson	Phase 2	27